Gastric CancerPhase 3KLASS-09NCT07437573
Oncometabolic Surgery
A Phase 3 study testing long-limb Roux-en-Y gastrojejunostomy in people with Gastric Cancer, run by Korea University Guro Hospital at 1 site in South Korea.
Trial summary
Recently, the concept of "Onco-metabolic surgery" has emerged, and it is a theory that if anastomosis bypassing the duodenum and upper jejunum is performed after gastrectomy in gastric cancer patients with type 2 diabetes, diabetes can be expected to improve. Read more about this study
- Who is it for?
- Ages 20 to 79 years
- Conditions the study is for
- Gastric Cancer
- What is being tested?
- long-limb Roux-en-Y gastrojejunostomy
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 94 participants
- Where
- 1 siteSouth Korea
- Study dates
- 7 Jul 2020to 7 May 2024
- Phase
- Phase 3
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 to 79 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Clinical Stage I Gastric Cancer
- a patient aged 20 to 80
- Dx of Type 2 Diabetes
- Preoperative BMI ≥ 23 kg/m2
Who cannot join
- If you have a history of cancer other than gastric cancer in the last five years
- If you received chemotherapy treatment before gastric cancer surgery
- Preoperative advanced gastric cancer is diagnosed, or gastric total resection is performed in the upper part
- If you have a history of malabsorption
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Comparison of the Long-limb vs. Conventional Roux-en-Y Reconstruction After Distal Gastrectomy in Gastric Cancer Patients With Type II Diabetes(Multicenter Prospective Randomized Controlled Study)
Recently, the concept of "Onco-metabolic surgery" has emerged, and it is a theory that if anastomosis bypassing the duodenum and upper jejunum is performed after gastrectomy in gastric cancer patients with type 2 diabetes, diabetes can be expected to improve. The authors would like to compare and analyze the effect of long bowel Luwai gastrointestinal anastomosis in gastric cancer patients with type 2 diabetes in a multicenter prospective manner with that of type 2 diabetes gastric cancer patients who underwent a conventional Luwai gastrointestinal anastomosis.
Read the detailed description
<Research Design>
- Primary Endpoint
- It examines whether there is a statistically significant difference in the proportion of patients with improved blood sugar control one year after surgery.
- Here, "Improvement of blood sugar control" includes all of the following three cases (complete remission, partial remission and improvement)
- IMPROVEMENT: Transition from insulin injection to oral hypoglycemic agents and reduction of diabetic medication dose due to reduction of glycated hemoglobin compared to preoperative
- Partial remission: Stop taking diabetes medication and maintain fasting blood glucose 100 to 125 and glycated hemoglobin 6 to 6.4
- Complete mission: Stop taking diabetes medication and maintain less than 100 fasting blood sugar and less than 6 glycated hemoglobin
- Secondary Endpoint
- Whether fasting blood glucose levels and glycated hemoglobin reduction at 1,3,6,12 months after surgery between the groups were significantly different
- Comparison of significant differences in changes in nutritional factors at 1, 3, 6, and 12 months after surgery between groups
- A Comparison of Significant Differences in Diabetes-Related Hormone Changes in 1, 3, and 12 Months After Surgery Between Groups
<Method of research>
- This study is a comparative study conducted with multicenter, prospective randomization.
- How to operate
- Before the start of surgery, the study group and the control group are selected by random assignment and the surgery is performed.
- The target groups that met the criteria for selection of the study are randomly divided into two groups (study group: long bowel Luwai anastomosis group, and control group: existing Luwai anastomosis group). The assignment of the two groups is to contact the institution to which the entire clinical trial director belongs, that is, the research nurse at Korea University Guro Hospital, to receive a military assignment after the subject of the study is registered for each institution and before surgery. Randomization is performed according to a table using https://www.sealedenvelope.com/ , and in order to ensure a balanced distribution between the two groups, stratified block randomization is performed by each institution participating in this clinical trial. Therefore, the study subjects will be randomly assigned to either the research group or the control group at a ratio of 1:1 within the participating institution.
- Research group (Long bowel Ruwai anastomosis group)
- Laparoscopic or robotic lower subtotal resection and extensive lymph node resection
- When performing the lower gastric subtotal resection, 70% of the total gastric volume should be resected and about 30% should be left including the bottom of the stomach.
- When performing Luwai-type anastomosis, the length of the biliary tract pancreatic branch, which is the field finger, is 80 centimeters, and the length of the blade finger from the stomach-factory anastomosis is 80 centimeters.
- Control (Existing Ruwai Anastomosis Group)
- Laparoscopic or robotic lower subtotal resection (70% resection) and extensive lymph node resection
- The length of the biliary tract pancreatic branch, which is a field finger, is 20 cm when performing the Luwai-type anastomosis according to the existing method Meter, the length of the blade from the upper-factory anastomosis part is 40 centimeters, and the upper-factory and factory- perform a jejunal anastomosis. Therefore, the difference in length between the two groups' diverted small intestine branches is 100 cm It's a meter.
- Analysis method Among the patients to be studied in this study, sex and age of the study group scheduled to perform a long bowel Luwai anastomosis and the control group patients scheduled to perform a conventional Luwai anastomosis, the medical history period of diabetes before surgery, body obesity at 1, 3, and 12 months before and after surgery, fasting blood sugar levels, and glycated hemoglobin levels are compared. Blood is collected for the preoperative and postoperative tests (30 minutes, 60 minutes, 120 minutes after loading) in the study group and the control group and the hormone and related components (insulin, C-peptide, Adiponectin, Leptin, Ghrelin, GLP-1, GIP, PYY) that are expected to be related to metabolic control and diabetes improvement effects are investigated and analyzed.
In addition, the degree of improvement in blood sugar control (no improvement, improvement: switching from insulin injection to oral hypoglycemic agents and reducing the dose of diabetic drugs, partial remission: maintaining fasting blood sugar from 100 to 125 without taking diabetic drugs, maintaining glycated hemoglobin 6 to 6.4 and complete remission: maintaining less than 100 fasting blood sugar without taking diabetic drugs) in the two groups is compared to examine the difference in blood sugar control effects according to changes in the length of anastomosis. In addition, we would like to conduct an analysis regarding the improvement of the plasma control effect to find out which factors can be the necessary requirements for improving diabetes control.
- Conditions
- Gastric Cancer
- Being tested
- long-limb Roux-en-Y gastrojejunostomy
- Medical subject headings
- Stomach Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
long-limb Roux-en-Y gastrojejunostomyProcedure or surgery
- Laparoscopic or robotic lower subtotal resection and extensive lymph node resection
- When performing the lower gastric subtotal resection, 70% of the total gastric volume should be resected and about 30% should be left including the bottom of the stomach.
- When performing Luwai-type anastomosis, the length of the biliary tract pancreatic branch, which is the field finger, is 80 centimeters, and the length of the blade finger from the stomach-factory anastomosis is 80 centimeters
| Study group | Role | What they receive |
|---|---|---|
| Multicenter Prospective Randomized Controlled Study | Active comparator | * Before the start of surgery, the study group and the control group are selected by random assignment and the surgery is performed.
* The target groups that met the criteria for selection of the study are randomly divided into two groups (study group: long bowel Luwai anastomosis group, and control group: existing Luwai anastomosis group). The assignment of the two groups is to contact the institution to which the entire clinical trial director belongs, that is, the research nurse at Korea University Guro Hospital, to receive a military assignment after the subject of the study is registered for each institution and before surgery. Receives: Procedure: long-limb Roux-en-Y gastrojejunostomy |
What is being measured
The primary outcome is the main question the study is designed to answer.
1)Primary Endpoint
Rate of more than improvement in diabetic control
- HbA1c <6.5%, FBS 125 mg/dL \& not increase in antidiabetic medication requirement
Measured: one year after surgery.
Secondary outcomes (1)
2)Secondary Endpoint
Concentration of HbA1c \& FBS in postoperative 1 year
Concentration of gut hormones related with diabetic control (Adiponectin, Ghrelin, Leptin, GLP-1 \& GIP)
Measured: one year after surgery.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 Feb 2026
- Study start7 Jul 2020
- Primary completion7 May 2024
- Study completion7 May 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Gastric CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 94 participants (actual)
Sponsor and investigators
- Lead sponsor
- Korea University Guro Hospital
- Sponsor type
- University, hospital or other
- Collaborators
- Kyungpook National University Chilgok Hospital, Samsung Medical Center, Asan Medical Center, Seoul National University Bundang Hospital, Kyung Hee University Hospital at Gangdong, Kosin University Gospel Hospital, Dankook University, Korea University Ansan Hospital, Seoul National University Hospital, Gangnam Severance Hospital, Keimyung University Dongsan Medical Center, Wonju Severance Christian Hospital, Gyeongsang National University Hospital
- Responsible party
- Principal investigator, Jong-Han Kim, Korea University Guro Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07437573
- Sponsor's protocol ID
- 2020GR0002
- Acronym
- KLASS-09
- Status last verified
- Feb 2026
- First submitted
- 27 Jan 2026
- Last updated
- 27 Feb 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: Age, gender, weight, BMI, Inbody (Option), duration of diabetes and diabetes treatment drugs, comorbidities other than diabetes, blood tests
Study at a glance
From the registry record, last updated by the sponsor on 27 Feb 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Comparison of the Long-limb vs. Conventional Roux-en-Y Reconstruction After Distal Gastrectomy in Gastric Cancer Patients With Type II Diabetes(Multicenter Prospective Randomized Controlled Study)
- ClinicalTrials.gov ID
- NCT07437573
- Acronym / sponsor ID
- KLASS-09 / 2020GR0002
- Conditions
- Gastric Cancer
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 94 participants (actual)
- Lead sponsor
- Korea University Guro HospitalUniversity, hospital or other
- Collaborators
- Kyungpook National University Chilgok Hospital, Samsung Medical Center, Asan Medical Center, Seoul National University Bundang Hospital, Kyung Hee University Hospital at Gangdong, Kosin University Gospel Hospital, Dankook University, Korea University Ansan Hospital, Seoul National University Hospital, Gangnam Severance Hospital, Keimyung University Dongsan Medical Center, Wonju Severance Christian Hospital, Gyeongsang National University Hospital
- Study start
- 7 Jul 2020 (actual)
- Primary completion
- 7 May 2024 (actual)
- Study completion
- 7 May 2024 (actual)
- First posted
- 27 Feb 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Recently, the concept of "Onco-metabolic surgery" has emerged, and it is a theory that if anastomosis bypassing the duodenum and upper jejunum is performed after gastrectomy in gastric cancer patients with type 2 diabetes, diabetes can be expected to improve. The authors would like to compare and analyze the effect of long bowel Luwai gastrointestinal anastomosis in gastric cancer patients with type 2 diabetes in a multicenter prospective manner with that of type 2 diabetes gastric cancer patients who underwent a conventional Luwai gastrointestinal anastomosis.
Detailed description
<Research Design>
- Primary Endpoint
- It examines whether there is a statistically significant difference in the proportion of patients with improved blood sugar control one year after surgery.
- Here, "Improvement of blood sugar control" includes all of the following three cases (complete remission, partial remission and improvement)
- IMPROVEMENT: Transition from insulin injection to oral hypoglycemic agents and reduction of diabetic medication dose due to reduction of glycated hemoglobin compared to preoperative
- Partial remission: Stop taking diabetes medication and maintain fasting blood glucose 100 to 125 and glycated hemoglobin 6 to 6.4
- Complete mission: Stop taking diabetes medication and maintain less than 100 fasting blood sugar and less than 6 glycated hemoglobin
- Secondary Endpoint
- Whether fasting blood glucose levels and glycated hemoglobin reduction at 1,3,6,12 months after surgery between the groups were significantly different
- Comparison of significant differences in changes in nutritional factors at 1, 3, 6, and 12 months after surgery between groups
- A Comparison of Significant Differences in Diabetes-Related Hormone Changes in 1, 3, and 12 Months After Surgery Between Groups
<Method of research>
- This study is a comparative study conducted with multicenter, prospective randomization.
- How to operate
- Before the start of surgery, the study group and the control group are selected by random assignment and the surgery is performed.
- The target groups that met the criteria for selection of the study are randomly divided into two groups (study group: long bowel Luwai anastomosis group, and control group: existing Luwai anastomosis group). The assignment of the two groups is to contact the institution to which the entire clinical trial director belongs, that is, the research nurse at Korea University Guro Hospital, to receive a military assignment after the subject of the study is registered for each institution and before surgery. Randomization is performed according to a table using https://www.sealedenvelope.com/ , and in order to ensure a balanced distribution between the two groups, stratified block randomization is performed by each institution participating in this clinical trial. Therefore, the study subjects will be randomly assigned to either the research group or the control group at a ratio of 1:1 within the participating institution.
- Research group (Long bowel Ruwai anastomosis group)
- Laparoscopic or robotic lower subtotal resection and extensive lymph node resection
- When performing the lower gastric subtotal resection, 70% of the total gastric volume should be resected and about 30% should be left including the bottom of the stomach.
- When performing Luwai-type anastomosis, the length of the biliary tract pancreatic branch, which is the field finger, is 80 centimeters, and the length of the blade finger from the stomach-factory anastomosis is 80 centimeters.
- Control (Existing Ruwai Anastomosis Group)
- Laparoscopic or robotic lower subtotal resection (70% resection) and extensive lymph node resection
- The length of the biliary tract pancreatic branch, which is a field finger, is 20 cm when performing the Luwai-type anastomosis according to the existing method Meter, the length of the blade from the upper-factory anastomosis part is 40 centimeters, and the upper-factory and factory- perform a jejunal anastomosis. Therefore, the difference in length between the two groups' diverted small intestine branches is 100 cm It's a meter.
- Analysis method Among the patients to be studied in this study, sex and age of the study group scheduled to perform a long bowel Luwai anastomosis and the control group patients scheduled to perform a conventional Luwai anastomosis, the medical history period of diabetes before surgery, body obesity at 1, 3, and 12 months before and after surgery, fasting blood sugar levels, and glycated hemoglobin levels are compared. Blood is collected for the preoperative and postoperative tests (30 minutes, 60 minutes, 120 minutes after loading) in the study group and the control group and the hormone and related components (insulin, C-peptide, Adiponectin, Leptin, Ghrelin, GLP-1, GIP, PYY) that are expected to be related to metabolic control and diabetes improvement effects are investigated and analyzed.
In addition, the degree of improvement in blood sugar control (no improvement, improvement: switching from insulin injection to oral hypoglycemic agents and reducing the dose of diabetic drugs, partial remission: maintaining fasting blood sugar from 100 to 125 without taking diabetic drugs, maintaining glycated hemoglobin 6 to 6.4 and complete remission: maintaining less than 100 fasting blood sugar without taking diabetic drugs) in the two groups is compared to examine the difference in blood sugar control effects according to changes in the length of anastomosis. In addition, we would like to conduct an analysis regarding the improvement of the plasma control effect to find out which factors can be the necessary requirements for improving diabetes control.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Multicenter Prospective Randomized Controlled Study | Active comparator | Procedure: long-limb Roux-en-Y gastrojejunostomy* Before the start of surgery, the study group and the control group are selected by random assignment and the surgery is performed. * The target groups that met the criteria for selection of the study are randomly divided into two groups (study group: long bowel Luwai anastomosis group, and control group: existing Luwai anastomosis group). The assignment of the two groups is to contact the institution to which the entire clinical trial director belongs, that is, the research nurse at Korea University Guro Hospital, to receive a military assignment after the subject of the study is registered for each institution and before surgery. |
Who may qualify
- Ages
- 20 to 79 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Clinical Stage I Gastric Cancer
- a patient aged 20 to 80
- Dx of Type 2 Diabetes
- Preoperative BMI ≥ 23 kg/m2
Key exclusion criteria (4 listed)
- If you have a history of cancer other than gastric cancer in the last five years
- If you received chemotherapy treatment before gastric cancer surgery
- Preoperative advanced gastric cancer is diagnosed, or gastric total resection is performed in the upper part
- If you have a history of malabsorption
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| long-limb Roux-en-Y gastrojejunostomy* Laparoscopic or robotic lower subtotal resection and extensive lymph node resection * When performing the lower gastric subtotal resection, 70% of the total gastric volume should be resected and about 30% should be left including the bottom of the stomach. * When performing Luwai-type anastomosis, the length of the biliary tract pancreatic branch, which is the field finger, is 80 centimeters, and the length of the blade finger from the stomach-factory anastomosis is 80 centimeters | Procedure or surgery | Multicenter Prospective Randomized Controlled Study |
Primary outcome
1)Primary Endpoint
Time frame: one year after surgery.
Rate of more than improvement in diabetic control - HbA1c <6.5%, FBS 125 mg/dL \& not increase in antidiabetic medication requirement
1 secondary outcome
2)Secondary Endpoint
Time frame: one year after surgery.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 27 Feb 2026.
- Individual participant dataSharing planned: Yes. Age, gender, weight, BMI, Inbody (Option), duration of diabetes and diabetes treatment drugs, comorbidities other than diabetes, blood tests
Related trials for Gastric Cancer
RecruitingPhase 2
Psilocybin-Assisted Psychotherapy in Cancer Patients With Adjustment Disorder
Adjustment Disorder, Adjustment Disorder With Anxious Mood
Not yet recruitingPhase 2
Serplulimab, DOS and Lenvatinib Combine With PIPAC in the Oligometastatic Peritoneal Metastasis of Gastric/Gastroesophageal Junction Adenocarcinoma
Gastric/Gastroesophageal Junction Adenocarcinoma, Oligometastatic Peritoneal Metastasis
Not yet recruitingPhase 2
Application of Intraperitoneal Hyperthermic Chemotherapy in the Treatment of Gastric Cancer With Peritoneal Metastasis
Gastric Cancer (Diagnosis)
Not yet recruitingObservational study
Lymph Node Dissection After Neoadjuvant Therapy for Gastric and EGJ Adenocarcinoma
Gastric Adenocarcinoma, Esophagogastric Junction Adenocarcinoma
RecruitingPhase 2
Non-covalent BTK Inhibitor Nemtabrutinib in Combination With the CD20 Monoclonal Antibody Rituximab for the Treatment of Marginal Zone Lymphoma
Conjunctival Mucosa-Associated Lymphoid Tissue Lymphoma, Gastric Mucosa-Associated Lymphoid Tissue Lymphoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing long-limb Roux-en-Y gastrojejunostomy in people with Gastric Cancer, run by Korea University Guro Hospital at 1 site in South Korea.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 27 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in South Korea. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
1)Primary Endpoint (time frame: one year after surgery.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Feb 2026.